These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 9486813)

  • 1. Gene therapy strategies for tumor antiangiogenesis.
    Kong HL; Crystal RG
    J Natl Cancer Inst; 1998 Feb; 90(4):273-86. PubMed ID: 9486813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor.
    Kong HL; Hecht D; Song W; Kovesdi I; Hackett NR; Yayon A; Crystal RG
    Hum Gene Ther; 1998 Apr; 9(6):823-33. PubMed ID: 9581905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo and ex vivo gene therapy strategies to treat tumors using adenovirus gene transfer vectors.
    Crystal RG
    Cancer Chemother Pharmacol; 1999; 43 Suppl():S90-9. PubMed ID: 10357566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin.
    Chen CT; Lin J; Li Q; Phipps SS; Jakubczak JL; Stewart DA; Skripchenko Y; Forry-Schaudies S; Wood J; Schnell C; Hallenbeck PL
    Hum Gene Ther; 2000 Sep; 11(14):1983-96. PubMed ID: 11020798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery of antiangiogenic agents for cancer gene therapy.
    Dickson PV; Nathwani AC; Davidoff AM
    Technol Cancer Res Treat; 2005 Aug; 4(4):331-41. PubMed ID: 16029054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenesis for cancer therapy.
    Harris AL
    Lancet; 1997 May; 349 Suppl 2():SII13-5. PubMed ID: 9164441
    [No Abstract]   [Full Text] [Related]  

  • 7. Suppression of angiogenesis: a means to fight cancer.
    Paillard F
    Hum Gene Ther; 1998 Apr; 9(6):768-70. PubMed ID: 9581899
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapeutic antitumor potential of endoglin-based DNA vaccine combined with immunomodulatory agents.
    Jarosz M; Jazowiecka-Rakus J; Cichoń T; Głowala-Kosińska M; Smolarczyk R; Smagur A; Malina S; Sochanik A; Szala S
    Gene Ther; 2013 Mar; 20(3):262-73. PubMed ID: 22495576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Why angiogenesis inhibition? Commentary.
    Boehm-Viswanathan T
    Int J Mol Med; 1999 Oct; 4(4):413-7. PubMed ID: 10493984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting tumor angiogenesis with gene therapy.
    Chen QR; Zhang L; Gasper W; Mixson AJ
    Mol Genet Metab; 2001; 74(1-2):120-7. PubMed ID: 11592809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor angiogenesis: biology and therapeutic prospects.
    Harris SR; Thorgeirsson UP
    In Vivo; 1998; 12(6):563-70. PubMed ID: 9891218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic delivery of the murine equivalent of bevacizumab (avastin), an anti-vascular endothelial growth factor monoclonal antibody, to suppress growth of human tumors in immunodeficient mice.
    Watanabe M; Boyer JL; Hackett NR; Qiu J; Crystal RG
    Hum Gene Ther; 2008 Mar; 19(3):300-10. PubMed ID: 18324912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest.
    Griscelli F; Li H; Bennaceur-Griscelli A; Soria J; Opolon P; Soria C; Perricaudet M; Yeh P; Lu H
    Proc Natl Acad Sci U S A; 1998 May; 95(11):6367-72. PubMed ID: 9600971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future prospects and challenges of antiangiogenic cancer gene therapy.
    Samaranayake H; Määttä AM; Pikkarainen J; Ylä-Herttuala S
    Hum Gene Ther; 2010 Apr; 21(4):381-96. PubMed ID: 20163246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenics meet nanotechnology.
    Ruoslahti E
    Cancer Cell; 2002 Aug; 2(2):97-8. PubMed ID: 12204528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of RGD-functionalized nonviral gene delivery vectors for cancer therapy.
    Park J; Singha K; Son S; Kim J; Namgung R; Yun CO; Kim WJ
    Cancer Gene Ther; 2012 Nov; 19(11):741-8. PubMed ID: 23018622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted antiangiogenesis gene therapy using targeted cationic microbubbles conjugated with CD105 antibody compared with untargeted cationic and neutral microbubbles.
    Zhou Y; Gu H; Xu Y; Li F; Kuang S; Wang Z; Zhou X; Ma H; Li P; Zheng Y; Ran H; Jian J; Zhao Y; Song W; Wang Q; Wang D
    Theranostics; 2015; 5(4):399-417. PubMed ID: 25699099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene therapy of murine solid tumors with T cells transduced with a retroviral vascular endothelial growth factor--immunotoxin target gene.
    Jin N; Chen W; Blazar BR; Ramakrishnan S; Vallera DA
    Hum Gene Ther; 2002 Mar; 13(4):497-508. PubMed ID: 11874628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene therapy for antiangiogenesis.
    Kleinman HK; Liau G
    J Natl Cancer Inst; 2001 Jul; 93(13):965-7. PubMed ID: 11438554
    [No Abstract]   [Full Text] [Related]  

  • 20. Cotargeting tumor and tumor endothelium effectively inhibits the growth of human prostate cancer in adenovirus-mediated antiangiogenesis and oncolysis combination therapy.
    Jin F; Xie Z; Kuo CJ; Chung LW; Hsieh CL
    Cancer Gene Ther; 2005 Mar; 12(3):257-67. PubMed ID: 15565180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.